Key result
Novel LC/MS/MS assay accurately quantifies omapatrilat and four metabolites across a 0.5-250 ng/mL range.
Why the study?
A validated method was needed for simultaneous determination of omapatrilat and its metabolites in human plasma to support development for hypertension and heart failure treatment.
Population
Human plasma samples
Comparison
Omapatrilat and its four metabolites with and without methyl acrylate stabilization
Design
LC/MS/MS method development and validation with semiautomated liquid-liquid extraction
Authors
Loading...
Validated LC/MS/MS assay enables omapatrilat PK studies in hypertension and HF; leaves open clinical adoption pending prospective validation.
An LC/MS/MS method was successfully developed and validated for the simultaneous determination of omapatrilat and its metabolites in human plasma.
Jemal et al. (2001) studied this question. LC/MS/MS method for omapatrilat determination was evaluated on Calibration curve ranges for omapatrilat and metabolites. An electrospray LC/MS/MS method was developed and validated for the simultaneous determination of omapatrilat and its four metabolites in human plasma, with calibration ranges of 0.5-250 ng/mL.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: